Transcription of Labelling Requirements for Investigational Medicinal ...
{{id}} {{{paragraph}}}
Labelling Requirements for Investigational Medicinal Products in Multinational Clinical Trials: Bureaucratic Cost Driver or Added Value? Wissenschaftliche Pr fungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen Fakult t der Rheinischen Friedrich-Wilhelms-Universit t Bonn vorgelegt von Dr. Astrid Weyermann aus Herford Bonn 2006 Dr. Astrid Weyermann Labelling Requirements for IMPs in multinational CTs Page 2 / 71 Betreuer und 1. Referent: H. Jopp Zweiter Referent: Dr. J. Hofer Dr. Astrid Weyermann Labelling Requirements for IMPs in multinational CTs Page 3 / 71 TABLE OF CONTENTS TABLE OF CONTENTS .. 3 1 EXECUTIVE 6 2 INTRODUCTION.
Dr. Astrid Weyermann Labelling requirements for IMPs in multinational CTs Page 6 / 71 1 EXECUTIVE SUMMARY The purpose of regulatory labelling requirements for investigational medicinal
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}